Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 19/20 | 0.66 |
| ▸ | EGFR | P00533 | 18/20 | 0.66 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
| ▸ | INSR | P06213 | 1/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.60 |
| ▸ | CDK2 | P24941 | 1/20 | 0.60 |
| ▸ | PLK1 | P53350 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17075832 | 0.97 | ERBB2 (0.69) | ERBB2EGFRABL1INSRPDGFRB | |
| SCHEMBL17075795 | 0.93 | EGFR (0.65) | ERBB2EGFRABL1INSRPDGFRB | |
| SCHEMBL17075841 | 0.90 | EGFR (0.57) | ERBB2EGFRABL1INSRPDGFRB | |
| SCHEMBL17075892 | 0.90 | ERBB2 (0.53) | ERBB2EGFRABL1INSRPDGFRB | |
| SCHEMBL17075827 | 0.89 | EGFR (0.63) | ERBB2EGFRABL1INSRPDGFRB | |
| SCHEMBL29563990 | 0.89 | EGFR (0.69) | ERBB2EGFRABL1INSRPDGFRB | |
| SCHEMBL17075815 | 0.89 | EGFR (0.69) | ERBB2EGFRABL1INSRPDGFRB | |
| SCHEMBL17075800 | 0.88 | EGFR (0.52) | ERBB2EGFRABL1INSRPDGFRB | |
| SCHEMBL17075850 | 0.88 | EGFR (0.64) | ERBB2EGFRABL1INSRPDGFRB | |
| SCHEMBL17075898 | 0.87 | ERBB2 (0.51) | ERBB2EGFRABL1INSRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150259331-A1 | PROTOZOAN PARASITE GROWTH INHIBITORS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259331-A1 | PROTOZOAN PARASITE GROWTH INHIBITORS | TPP1, MKI67, PIGO | ERBB2 4468/4885EGFR 4389/4885ABL1 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.